Thomas A Ciulla (Thomas Ciulla)

Scopus Author ID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 34

Top Venues

Expert opinion on biological therapy

Genes

The British journal of ophthalmology

Ocular immunology and inflammation

Clearside Biomedical (United States)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Clearside Biomedical (United States)

United States

Chief Medical Officer and Chief Development Officer

Indiana University School of Medicine

United States

Volunteer Clinical Professor :: Ophthalmology

Midwest Eye Institute

United States

Retina Physician, Board Member :: Retina Service

Spark Therapeutics (United States)

United States

V.P., Medical Strategy Lead, Ophthalmology

Ophthotech (United States)

United States

V.P., Clinical Strategy

Indiana University School of Medicine

United States

Associate Professor :: Ophthalmology

Indiana University School of Medicine

United States

Assistant Professor :: Ophthalmology

Publications

Lucas W Rowe, Thomas A Ciulla
Long-acting delivery and therapies for neovascular age-related macular degeneration. Expert opinion on biological therapy (2024)
Milan Shah, Thomas Albini, Quan Nguyen, Charles Wykoff, Mark Barakat, Rahul N Khurana, Barry Kapik, Thomas A Ciulla
Safety and Efficacy of CLS-TA by Anatomic Location of Inflammation: Results from the Phase 3 PEACHTREE Clinical Trial. Ocular immunology and inflammation (2024)
Jay Maturi, Vikas Maturi, Adrienne W Scott, Kathryn A Carson, Thomas A Ciulla, Raj Maturi
Effect of Race and Insurance Status on Treatment and Outcomes in Diabetic Retinopathy: Analysis of 43 274 Eyes Using the IRIS Registry. Journal of vitreoretinal diseases 8 (3) (2024)
Lucas W Rowe, Thomas A Ciulla
Gene Therapy for Non-Hereditary Retinal Disease: Age-Related Macular Degeneration, Diabetic Retinopathy, and Beyond. Genes 15 (6) (2024)
Jay Maturi, Vikas Maturi, Adrienne W Scott, Kathryn A Carson, Thomas A Ciulla, Raj Maturi
Effect of Race and Insurance Status on Treatment and Outcomes in Diabetic Retinopathy: Analysis of 43 274 Eyes Using the IRIS Registry. Journal of vitreoretinal diseases 8 (3) (2024)
Lucas W Rowe, Thomas A Ciulla
Gene Therapy for Non-Hereditary Retinal Disease: Age-Related Macular Degeneration, Diabetic Retinopathy, and Beyond. Genes 15 (6) (2024)
Milan Shah, Thomas Albini, Quan Nguyen, Charles Wykoff, Mark Barakat, Rahul Khurana, Barry Kapik, Thomas A Ciulla
Safety and Efficacy of CLS-TA by Anatomic Location of Inflammation: Results from the Phase 3 PEACHTREE Clinical Trial. Ocular immunology and inflammation (2024)
Lucas W Rowe, Thomas A Ciulla
Long-acting delivery and therapies for neovascular age-related macular degeneration. Expert opinion on biological therapy 24 (8) (2024)
Janet C Coleman-Belin, Alon Harris, Bo Chen, Jing Zhou, Thomas A Ciulla, Alice Verticchio, Gal Antman, Michael Chang, Brent Siesky
Aging Effects on Optic Nerve Neurodegeneration. International journal of molecular sciences 24 (3) (2023)
Aumer Shughoury, Duriye D Sevgi, Thomas A Ciulla
The complement system: a novel therapeutic target for Age-related macular degeneration. Expert opinion on pharmacotherapy (2023)
Aumer Shughoury, Ashay Dilip Bhatwadekar, Denis Jusufbegovic, Amir Hajrasouliha, Thomas A Ciulla
The evolving therapeutic landscape of diabetic retinopathy. Expert opinion on biological therapy (2023)
Janet C Coleman-Belin, Alon Harris, Bo Chen, Jing Zhou, Thomas A Ciulla, Alice Verticchio, Gal Antman, Michael Chang, Brent Siesky
Aging Effects on Optic Nerve Neurodegeneration. International journal of molecular sciences 24 (3) (2023)
Janet C Coleman-Belin, Alon Harris, Bo Chen, Jing Zhou, Thomas A Ciulla, Alice Verticchio, Gal Antman, Michael Chang, Brent Siesky
Aging Effects on Optic Nerve Neurodegeneration. International journal of molecular sciences 24 (3) (2023)
Kyle D Kovacs, Thomas A Ciulla, Szilárd Kiss
Advancements in ocular gene therapy delivery: vectors and subretinal, intravitreal, and suprachoroidal techniques. Expert opinion on biological therapy 22 (9) (2022)
Aditya Belamkar, Alon Harris, Ryan Zukerman, Brent Siesky, Francesco Oddone, Alice Verticchio Vercellin, Thomas A Ciulla
Sustained release glaucoma therapies: Novel modalities for overcoming key treatment barriers associated with topical medications. Annals of medicine 54 (1) (2022)
Steven Yeh, Christopher Ryan Henry, Barry Kapik, Thomas A Ciulla
Triamcinolone Acetonide Suprachoroidal Injectable Suspension for Uveitic Macular Edema: Integrated Analysis of Two Phase 3 Studies. Ophthalmology and therapy (2022)
Amber T Wolf, Alon Harris, Francesco Oddone, Brent Siesky, Alice Verticchio Vercellin, Thomas A Ciulla
Disease progression pathways of wet AMD: opportunities for new target discovery. Expert opinion on therapeutic targets 26 (1) (2022)
Shivam H Patel, Aditya Belamkar, Amir R Hajrasouliha, Denis Jusufbegovic, Thomas A Ciulla
Progress in the pharmacotherapy of uveitis: the art of personalized care. Expert opinion on pharmacotherapy 23 (12) (2022)
Pauline T Merrill, Christopher R Henry, Quan Dong Nguyen, Ashvini Reddy, Barry Kapik, Thomas A Ciulla
Suprachoroidal CLS-TA with and without Systemic Corticosteroid and/or Steroid-Sparing Therapy: A Post-Hoc Analysis of the Phase 3 PEACHTREE Clinical Trial. Ocular immunology and inflammation (2021)
Michael A Singer, Pauline Merrill, Steven Yeh, Colette Hall, Barry Kapik, Thomas A Ciulla
Suprachoroidal CLS-TA versus Rescue Therapies for the Treatment of Uveitic Macular Edema: A Post Hoc Analysis of PEACHTREE. Clinical & experimental ophthalmology (2021)
Rahul N Khurana, Pauline T Merrill, Steven Yeh, Eric Suhler, Mark R Barakat, Eduardo Uchiyama, Christopher Ryan Henry, Milan Shah, Robert C Wang, Barry Kapik, Thomas A Ciulla
Extension study of the safety and efficacy of CLS-TA for treatment of macular oedema associated with non-infectious uveitis (MAGNOLIA). The British journal of ophthalmology (2021)
Christopher Ryan Henry, Milan Shah, Mark R Barakat, Pouya Dayani, Robert C Wang, Rahul N Khurana, Lana Rifkin, Steven Yeh, Colette Hall, Thomas A Ciulla
Suprachoroidal CLS-TA for non-infectious uveitis: an open-label, safety trial (AZALEA). The British journal of ophthalmology (2021)
Ryan Zukerman, Alon Harris, Francesco Oddone, Brent Siesky, Alice Verticchio Vercellin, Thomas A Ciulla
Glaucoma Heritability: Molecular Mechanisms of Disease. Genes 12 (8) (2021)
Sameer P Leley, Thomas A Ciulla, Ashay Dilip Bhatwadekar
Diabetic Retinopathy in the Aging Population: A Perspective of Pathogenesis and Treatment. Clinical interventions in aging 16 (2021)
Ashay Dilip Bhatwadekar, Aumer Shughoury, Ameya Belamkar, Thomas A Ciulla
Genetics of Diabetic Retinopathy, a Leading Cause of Irreversible Blindness in the Industrialized World. Genes 12 (8) (2021)
Shelley E Hancock, Chen-Rei Wan, Nathan E Fisher, Rafael V Andino, Thomas A Ciulla
Biomechanics of suprachoroidal drug delivery: From benchtop to clinical investigation in ocular therapies. Expert opinion on drug delivery 18 (6) (2021)
Chen-Rei Wan, Leroy Muya, Viral Kansara, Thomas A Ciulla
Suprachoroidal Delivery of Small Molecules, Nanoparticles, Gene and Cell Therapies for Ocular Diseases. Pharmaceutics 13 (2) (2021)
Thomas A Ciulla, John S Pollack, David F Williams
Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes. The British journal of ophthalmology 105 (2) (2020)
Ryan Zukerman, Alon Harris, Alice Verticchio Vercellin, Brent Siesky, Louis R Pasquale, Thomas A Ciulla
Molecular Genetics of Glaucoma: Subtype and Ethnicity Considerations. Genes 12 (1) (2020)
Michael C Gemayel, Ashay Dilip Bhatwadekar, Thomas A Ciulla
RNA therapeutics for retinal diseases. Expert opinion on biological therapy 21 (5) (2020)
Thomas A Ciulla, Rehan M Hussain, Audina M Berrocal, Aaron Nagiel
Voretigene neparvovec-rzyl for treatment of RPE65-mediated inherited retinal diseases: a model for ocular gene therapy development. Expert opinion on biological therapy 20 (6) (2020)
Michael Gemayel, Ashley Neiweem, Brent Aebi, Peter Bracha, Thomas A Ciulla
Microbial Spectrum and Antibacterial Susceptibility of Endophthalmitis Cultures in a Tertiary Referral Center in the Midwestern United States: An Analysis From 295 Patients. Journal of vitreoretinal diseases 5 (3) (2020)
Thomas A Ciulla, John S Pollack, David F Williams
Visual acuity outcomes and anti-VEGF therapy intensity in macular oedema due to retinal vein occlusion: a real-world analysis of 15 613 patient eyes. The British journal of ophthalmology 105 (12) (2020)
Ashay Dilip Bhatwadekar, Viral Kansara, Qianyi Luo, Thomas A Ciulla
Anti-integrin therapy for retinovascular diseases. Expert opinion on investigational drugs 29 (9) (2020)

Thomas A Ciulla.css-eqlu8i{font-size:small;padding-left:4px;} (Thomas Ciulla)

Publication Activity (10 Years)

Top Topics

Top Venues

Thomas A Ciulla (Thomas Ciulla)